News Briefing channel feed

Rigel steps back from sN­DA fil­ing plans for bleed­ing dis­or­der drug; NMD gives first look in­to myas­the­nia gravis pro­gram

3 years ago

Astel­las, Pan­th­er­na add or­gan to mR­NA tie-up; Rock­et launch­es sale of six fig­ures worth of stock

3 years ago
R&D

No­vo Nordisk touts an­oth­er once-week­ly in­sulin win; Mere­o's board bat­tle heats up again

3 years ago

Aim­ing for fourth nod, Sarep­ta files an­oth­er DMD gene ther­a­py to FDA; Ax­some head­ed to­ward mi­graine re­sub­mis­sion

3 years ago

Gami­da Cell prices its fol­low-on pub­lic of­fer­ing at $20M; Rally­bio touts Phase Ib da­ta for mon­o­clon­al an­ti­body

3 years ago

Seagen and Zai Lab ink part­ner­ship on Tiv­dak ex­pan­sion in­to Chi­na and sur­round­ing ar­eas; NC biotech snaps up seed fund­ing

3 years ago

Lipocine shifts fo­cus to CNS; Drug ap­proval trig­gers cap­i­tal in­fu­sion at Fen­nec

3 years ago

Pfiz­er and Sang­amo re-open PhI­II of he­mo­phil­ia A gene ther­a­py; AEON head­ed to PhI­II

3 years ago

Mer­ck and As­traZeneca get Lyn­parza OK in Chi­na for new in­di­ca­tion; BAR­DA ex­er­cis­es first op­tion with Mar­i­nus

3 years ago

Alpine eyes $100M cap­i­tal in­fu­sion; Bob Dug­gan lends $65M to cos­met­ics com­pa­ny-turned-biotech

3 years ago

Menar­i­ni Group and Sci­Clone Phar­ma­ceu­ti­cals ink deal to com­mer­cial­ize drug in Chi­na; Cel­sion to change its name

3 years ago

Re­jec­tion No. 2 for Medexus' decades-old chemo drug; Tre­vi touts chron­ic cough da­ta

3 years ago

Mallinck­rodt se­cures FDA ap­proval — but not with­out warn­ing; Rhythm seeks $100M af­ter reg­u­la­to­ry OKs

3 years ago

Two biotechs go for pub­lic of­fer­ings; Pfiz­er part­ner ex­pands on­col­o­gy col­lab

3 years ago

Io­n­is, As­traZeneca go­ing to FDA with PhI­II da­ta in hand; Glaukos touts dou­ble PhI­II win in eye im­plant

3 years ago

FDA's out­side ex­perts to re­view GSK, As­traZeneca drugs; Biotech gives very ear­ly pos­i­tive in­di­ca­tions for cell ther­a­py

3 years ago

Shang­hai-based cell ther­a­py biotech nabs new funds; Col­orado biotech nets an ac­qui­si­tion

3 years ago
Financing
China

Foghorn co-founder re­signs from board; Guardant and Mer­ck KGaA team up again

3 years ago

Sau­di an­ti-ag­ing group links up with AFAR to dole out re­search grants; US cannabis biotech se­cures UK part­ner

3 years ago

Food al­ler­gy biotech gets $50M loan; Sean Ianchulev’s med­ical de­vice com­pa­ny rais­es a $23M Se­ries B

3 years ago

Small neu­rol­o­gy biotech an­nounces prices its $8M IPO; Vivos put on no­tice af­ter miss­ing fil­ing dead­line

3 years ago

Bei­jing CRO ex­pands agree­ment with Mer­ck KGaA; Ear­ly-stage ven­ture firm clos­es its first fund

3 years ago

Wom­en's health biotech nabs new an­timi­cro­bial treat­ment; Ovid finds part­ner for neu­ro­science col­lab­o­ra­tion

3 years ago

No Q2 call yet for a Col­orado medtech; San Diego biotech col­labs with MD An­der­son

3 years ago
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times